A new hepatoma cell line for toxicity testing at repeated doses.
Many cell models that are used to assess basic cytotoxicity show a good correlation with acute toxicity. However, their correlation with the toxicity seen following chronic in vivo exposure is less evident. The new human hepatoma cell line HBG BC2 possesses the capacity of being reversibly differentiated in vitro and of maintaining a relatively higher metabolic rate when in the differentiated state (3 weeks) as compared to HepG2 cells, and thus may allow the conduct of repeated toxicity testing on cells in culture. In order to evaluate the genetic background of HBG BC2 cells, the expression of selected genes was analyzed in untreated cultures and, in addition, the behavior of HBG BC2 cultures under conditions of repeated treatment was studied with acetaminophen as a test substance and coupled with the use of standard staining techniques to demonstrate toxicity. Results showed that cultures of HBG BC2 cells retained a capacity to undergo apoptosis and proliferation, allowing probable replacement of damaged cells in the culture monolayer. MTT reduction was used to evaluate the toxicity of acetaminophen, acetylsalicylic acid, perhexiline, and propranolol, after both single and repeated (3 times/week for 2 weeks) administration. Under the conditions of repeated treatment, cytotoxicity was observed at lower doses as compared to single administration. In addition, the lowest nontoxic doses were in the same range as plasma concentrations measured in humans under therapeutic use. Our results suggest that the new human hepatoma HBG BC2 cell line is of interest for the evaluation of cell toxicity under conditions of repeated administration.
Fabre
N
N
Sanofi-Synthelabo Recherche, Department of Toxicology-Porcheville, Porcheville, France. nicolas.fabre@sanofi-synthelabo.com
Arrivet
E
E
Trancard
J
J
Bichet
N
N
Roome
N O
NO
Prenez
A
A
Vericat
J A
JA
D000082:Acetaminophen / Q000633:toxicity; D001241:Aspirin / Q000633:toxicity; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D010480:Perhexiline / Q000633:toxicity; D011433:Propranolol / Q000633:toxicity; D018675:Toxicity Tests
D000082:Acetaminophen; D011433:Propranolol; D010480:Perhexiline; D001241:Aspirin